Toll Free: 1-888-928-9744

Acne Vulgaris - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 177 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acne Vulgaris - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 21, 6, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Acne Vulgaris - Overview 8 Acne Vulgaris - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Acne Vulgaris - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Acne Vulgaris - Companies Involved in Therapeutics Development 30 3SBio Inc 30 Allergan Plc 30 Almirall SA 31 Biomar Microbial Technologies 31 BioPharmX Inc 32 Braintree Laboratories Inc 32 Brickell Biotech Inc 33 Cassiopea SpA 33 Cell Medica Ltd 34 Cellceutix Corp 34 Celtaxsys Inc 35 Common Pharma Inc 35 Cutanea Life Sciences Inc 36 Dermira Inc 36 ELORAC Inc 37 Ensol Biosciences Inc 37 Foamix Pharmaceuticals Ltd 38 Galderma SA 38 GlaxoSmithKline Plc 39 Helix BioMedix Inc 39 Hovione FarmaCiencia SA 40 Lee's Pharmaceutical Holdings Ltd 40 LEO Pharma A/S 41 Novabiotics Ltd 41 Novan Inc 42 Novartis AG 42 Paratek Pharmaceuticals Inc 43 Pfizer Inc 43 Phosphagenics Ltd 44 Photocure ASA 44 Promius Pharma LLC 45 Provectus Biopharmaceuticals Inc 45 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 46 Sol-Gel Technologies Ltd 46 Sun Pharma Advanced Research Company Ltd 47 Valeant Pharmaceuticals International Inc 47 Vectura Group Plc 48 Vyome Biosciences Pvt Ltd 48 XBiotech Inc 49 Acne Vulgaris - Drug Profiles 50 (adapalene + clindamycin hydrochloride) - Drug Profile 50 (benzoyl peroxide + tretinoin) - Drug Profile 51 (clindamycin phosphate + tretinoin) - Drug Profile 52 acebilustat - Drug Profile 53 Aczone Combo - Drug Profile 57 aminolevulinic acid hydrochloride - Drug Profile 58 AQ-401 - Drug Profile 59 B-244 - Drug Profile 60 BBI-3000 - Drug Profile 62 benzoyl peroxide - Drug Profile 63 BLI-1100 - Drug Profile 64 brilacidin tetrahydrochloride - Drug Profile 65 carbamide peroxide - Drug Profile 76 CB-0301 - Drug Profile 77 CB-0601 - Drug Profile 80 CJM-112 - Drug Profile 81 CLS-007 - Drug Profile 82 dapsone - Drug Profile 83 DFD-10 - Drug Profile 84 DLX-2323 - Drug Profile 85 DLX-2681 - Drug Profile 86 DMT-210 - Drug Profile 87 DMT-310 - Drug Profile 88 DX-0385 - Drug Profile 89 finasteride - Drug Profile 90 FMX-101 - Drug Profile 91 GSK-1940029 - Drug Profile 94 HB-1345 - Drug Profile 95 Hesed-4000 - Drug Profile 96 IB-07A037 - Drug Profile 97 IDP-120 - Drug Profile 98 IDP-121 - Drug Profile 99 IDP-123 - Drug Profile 100 IDP-126 - Drug Profile 101 IDP-129 - Drug Profile 102 IDP-130 - Drug Profile 103 ingenol disoxate - Drug Profile 104 ivermectin - Drug Profile 106 K-1032 - Drug Profile 107 LTA-001 - Drug Profile 108 methyl aminolevulinate hydrochloride - Drug Profile 109 minocycline - Drug Profile 111 minocycline - Drug Profile 112 minocycline hydrochloride - Drug Profile 116 MTC-896 - Drug Profile 117 olumacostat glasaretil - Drug Profile 119 omiganan pentahydrochloride - Drug Profile 124 Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 126 PF-06423264 - Drug Profile 127 PH-10 - Drug Profile 128 RA-18C3 - Drug Profile 131 sarecycline hydrochloride - Drug Profile 133 SB-204 - Drug Profile 135 SKP-026 - Drug Profile 140 Small Molecule for Acne and Skin Inflammation - Drug Profile 141 Small Molecule to Agonise NR1C3 for Acne Vulgaris - Drug Profile 142 Small Molecules for Acne Vulgaris - Drug Profile 143 Synthetic Peptide for Acne Vulgaris - Drug Profile 144 Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 145 tazarotene - Drug Profile 146 tretinoin - Drug Profile 147 tretinoin - Drug Profile 149 trifarotene - Drug Profile 150 Vaccine for Acne Vulgaris - Drug Profile 152 VB-1953 - Drug Profile 153 Acne Vulgaris - Dormant Projects 154 Acne Vulgaris - Discontinued Products 159 Acne Vulgaris - Product Development Milestones 160 Featured News & Press Releases 160 Appendix 171 Methodology 171 Coverage 171 Secondary Research 171 Primary Research 171 Expert Panel Validation 171 Contact Us 171 Disclaimer 172
List of Tables
Number of Products under Development for Acne Vulgaris, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Acne Vulgaris - Pipeline by 3SBio Inc, H1 2017 Acne Vulgaris - Pipeline by Allergan Plc, H1 2017 Acne Vulgaris - Pipeline by Almirall SA, H1 2017 Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2017 Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2017 Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H1 2017 Acne Vulgaris - Pipeline by Brickell Biotech Inc, H1 2017 Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2017 Acne Vulgaris - Pipeline by Cell Medica Ltd, H1 2017 Acne Vulgaris - Pipeline by Cellceutix Corp, H1 2017 Acne Vulgaris - Pipeline by Celtaxsys Inc, H1 2017 Acne Vulgaris - Pipeline by Common Pharma Inc, H1 2017 Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2017 Acne Vulgaris - Pipeline by Dermira Inc, H1 2017 Acne Vulgaris - Pipeline by ELORAC Inc, H1 2017 Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H1 2017 Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017 Acne Vulgaris - Pipeline by Galderma SA, H1 2017 Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H1 2017 Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2017 Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2017 Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017 Acne Vulgaris - Pipeline by LEO Pharma A/S, H1 2017 Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2017 Acne Vulgaris - Pipeline by Novan Inc, H1 2017 Acne Vulgaris - Pipeline by Novartis AG, H1 2017 Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H1 2017 Acne Vulgaris - Pipeline by Pfizer Inc, H1 2017 Acne Vulgaris - Pipeline by Phosphagenics Ltd, H1 2017 Acne Vulgaris - Pipeline by Photocure ASA, H1 2017 Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2017 Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017 Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017 Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2017 Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017 Acne Vulgaris - Pipeline by Vectura Group Plc, H1 2017 Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H1 2017 Acne Vulgaris - Pipeline by XBiotech Inc, H1 2017 Acne Vulgaris - Dormant Projects, H1 2017 Acne Vulgaris - Dormant Projects, H1 2017 (Contd..1), H1 2017 Acne Vulgaris - Dormant Projects, H1 2017 (Contd..2), H1 2017 Acne Vulgaris - Dormant Projects, H1 2017 (Contd..3), H1 2017 Acne Vulgaris - Dormant Projects, H1 2017 (Contd..4), H1 2017 Acne Vulgaris - Discontinued Products, H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify